DEC 14, 2017 8:00 AM PST

WEBINAR: Emergence of Clinical Proteomics: Identifying and developing actionable protein biomarkers for use in clinical research.

Sponsored by: Thermo Fisher Scientific
Speakers
  • President of Proteomics, NantOmics
    Biography
      Todd Hembrough, PhD is the President, Proteomics at NantOmics where he oversees R&D, operations, and the clinical proteomics laboratory. Todd obtained his Ph.D. in Biochemistry from the University of Virginia, studying the role of proteinases in tumor growth and invasion. Prior to NantOmics, Todd was a leader of the translational oncology efforts at EntreMed, focusing on defining druggable molecular pathways and inventing new drugs to target these pathways. Todd later became the Chief Scientific Officer and Head of R&D at OncoPlex Diagnostics and Expression Pathology where he helped lead the development and commercial launch of the first quantitative proteomic assays performed on formalin-fixed, paraffin-embedded tissue.
    • Manager, Assay Development, NantOmics
      Biography
        Maryann Vogelsang, PhD leads the assay development team, and drives the implementation and delivery of NantOmics' mass spectrometry (MS)-based assay development pipeline for both R&D and clinical proteomics laboratories. Maryann earned her PhD in Biochemistry and Molecular Biology from the University of California, Los Angeles. Prior to NantOmics, Maryann established a CLIA compliant laboratory that offered both ELISA- and MS-based clinical assays. She has over a decade of experience in translational medicine utilizing the mass spectrometry platform, and spent a significant part of her career as a scientist developing workflows that facilitate proteomics biomarker discovery and validation processes at the Thermo Fisher Scientific BRIMS Center.

      Abstract

      DATE: December 14, 2017
      TIME: 08:00am PST, 11:00am EST, 4:00pm BST, 5:00pm CEST

      The benefits of genomic analysis are well understood, however, the majority of patients do not harbor druggable alterations in their genomes and thus are not candidates for targeted therapies.  In patients whose tumors lack genomic biomarkers for targeted therapies or have developed resistance, clinical proteomics is identifying protein biomarkers for therapies that are benefitting patients—thus fueling the emergence of proteogenomics. 

      We have built more than 250 quantitative proteomic assays for relevant oncology biomarkers expressed in solubilized, formalin-fixed, paraffin-embedded tumor samples using selected reaction monitoring mass spectrometry.  This webinar will cover the assay development pipeline utilized to bring these quantitative proteomic markers into our CAP-CLIA laboratory.  Starting from a targeted-discovery initiative to the analytical validation of our multiplexed SRM methods, we will discuss the metrics used to validate our assays. 

      Additionally, this webinar will introduce the impact these developed markers have on clinical research, including the retrospective analyses of HER2 proteomic expression in adjuvant and metastatic breast cancer and in advanced gastric cancer.  The HER2 proteomic expression levels correlated with response to trastuzumab.  From this correlation, we were able to identify a proteomic cut-off value of response.  This potential benefit extended to donors identified as non-breast/non-gastric cancer patients who overexpressed HER2 and who subsequently responded to HER2-targeted therapy.

      Key Learning Objectives:

      • Metrics used to analytically validate a multiplexed proteomic LC-MS assay.
      • Workflows and processes used in working with Liquid Tissue®.
      • The clinical impact on delivering much needed biomarkers of therapeutic response.

      Show Resources
      You May Also Like
      DEC 02, 2020 8:00 AM PST
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      C.E. CREDITS
      DEC 02, 2020 8:00 AM PST
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
      OCT 08, 2020 7:00 AM PDT
      C.E. CREDITS
      OCT 08, 2020 7:00 AM PDT
      DATE: October 8, 2020 TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop thinking about ho...
      AUG 25, 2020 8:00 AM PDT
      C.E. CREDITS
      AUG 25, 2020 8:00 AM PDT
      DATE: August 25, 2020 TIME: 8:00am PDT, 10:00am CDT, 11:00am EDT Recombinant lentivirus (LV) and adeno-associated virus (AAV) are critical components of cell and gene therapies, which show g...
      SEP 10, 2020 9:00 AM PDT
      C.E. CREDITS
      SEP 10, 2020 9:00 AM PDT
      Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
      NOV 16, 2020 8:00 AM PST
      C.E. CREDITS
      NOV 16, 2020 8:00 AM PST
      Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
      OCT 29, 2020 6:00 AM PDT
      C.E. CREDITS
      OCT 29, 2020 6:00 AM PDT
      Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
      Loading Comments...
      Show Resources